Trials / Unknown
UnknownNCT04990271
A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Months – 5 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, multi-center, open single-arm Phase II clinical trial is designed to investigate the efficacy and safety of intravenous chemotherapy combined with Conbercept intravitreal injection in the treatment of retinoblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Conbercept ophthalmic injection | Monthly injection of Conbercept from 0\~5 months |
Timeline
- Start date
- 2021-07-05
- Primary completion
- 2023-04-15
- Completion
- 2023-07-15
- First posted
- 2021-08-04
- Last updated
- 2021-08-04
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04990271. Inclusion in this directory is not an endorsement.